8-K: Kezar Life Sciences Reports Positive Topline Data from AIH Trial and Provides Business Update

Kezar Life Sciences announced positive topline data from its PORTOLA Phase 2a clinical trial for autoimmune hepatitis (AIH) and reported a cash balance of $114.4 million as of March 31, 2025.

Summary

• Kezar Life Sciences reported financial results for the first quarter ended March 31, 2025.
• The company shared positive topline data from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH).
• As of March 31, 2025, Kezar had $114.4 million in cash, cash equivalents, and marketable securities.
• In the PORTOLA trial, 36% (5 of 14) of zetomipzomib-treated patients with relapsed AIH achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 placebo patients.
• In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper, compared to 1 of 8 placebo patients.
• The median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks.
• Research and development (R&D) expenses for the first quarter of 2025 decreased by $5.0 million to $12.2 million, compared to $17.2 million in the first quarter of 2024.
• General and administrative (G&A) expenses for the first quarter of 2025 decreased by $1.1 million to $5.4 million compared to $6.5 million in the first quarter of 2024.
• Net loss for the first quarter of 2025 was $16.6 million, or $2.27 per basic and diluted common share, compared to a net loss of $21.7 million, or $2.98 per basic and diluted common share, for the first quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial data and a decrease in net loss, but the partial clinical hold and termination of another trial temper the overall sentiment. The company's cash position provides financial stability.

Positives

• Positive topline data from the PORTOLA Phase 2a clinical trial for AIH was reported.
• A favorable safety profile was observed during the 6-month blinded treatment period of the PORTOLA trial.
• The company has a substantial cash position of $114.4 million.
• Net loss decreased in Q1 2025 compared to Q1 2024.
• R&D and G&A expenses decreased in Q1 2025 compared to Q1 2024.

Negatives

• The PORTOLA Phase 2a clinical trial is currently under a partial clinical hold by the FDA.
• The PALIZADE Phase 2b clinical trial for lupus nephritis was terminated following a clinical hold by the FDA.
• The company experienced a net loss of $16.6 million for the first quarter of 2025.
• Cash, cash equivalents, and marketable securities decreased from $132.2 million as of December 31, 2024, to $114.4 million as of March 31, 2025.

Risks

• The partial clinical hold on the PORTOLA Phase 2a clinical trial could delay or prevent further development of zetomipzomib for AIH.
• The company needs to achieve alignment with the FDA on an appropriate trial design to demonstrate the clinical benefit of zetomipzomib in AIH.
• Unexpected safety or efficacy data observed during clinical studies could negatively impact the development of Kezar's product candidates.
• Changes in the regulatory environment could impact the approval process for Kezar's product candidates.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Kezar is working toward achieving alignment with the FDA on an appropriate trial design to demonstrate the clinical benefit of zetomipzomib in AIH and expects to initiate a registrational trial.

Management Comments

• Chris Kirk, CEO and co-founder of Kezar, stated that the PORTOLA trial showed exciting results and is the first successful randomized study in treatment-refractory AIH.
• Kirk noted the lack of change in AIH treatment over the last three decades and the need for new and effective therapies.
• Kirk expressed encouragement regarding the promising safety and efficacy data, particularly the durable and steroid-sparing remissions observed in patients treated with zetomipzomib.

Industry Context

The announcement highlights the unmet need for new and effective therapies in autoimmune hepatitis, a chronic disease with limited treatment options. Kezar's zetomipzomib aims to address this need with a novel approach.

Comparison to Industry Standards

• The 36% complete response rate with steroid taper in relapsed AIH patients in the PORTOLA trial compares favorably to existing standard of care treatments, which often have limited efficacy and significant side effects.
• Companies like CymaBay Therapeutics and Intercept Pharmaceuticals are also developing therapies for liver diseases, but Kezar's focus on immunoproteasome inhibition represents a distinct mechanism of action.
• The median duration of response of 27.6 weeks is a key metric to watch, as durability of response is critical for chronic diseases like AIH.

Stakeholder Impact

• Positive clinical trial results could benefit patients with autoimmune hepatitis by providing a new treatment option.
• Shareholders may react positively to the positive topline data and decreased net loss.
• Employees may be affected by the strategic decision to focus on AIH and terminate the lupus nephritis trial.

Next Steps

• Kezar will continue to respond to the FDA's information request to resolve the partial clinical hold on the PORTOLA Phase 2a clinical trial.
• The company aims to achieve alignment with the FDA on an appropriate trial design to demonstrate the clinical benefit of zetomipzomib in AIH.
• Kezar expects to initiate a registrational trial of zetomipzomib in AIH.

Key Dates

Keywords

Kezar Life Sciences, Zetomipzomib, Autoimmune Hepatitis, AIH, PORTOLA Trial, Lupus Nephritis, Clinical Trial, Financial Results, Biotechnology, FDA